Chen Jun, Li Jian-Hao, Zhao Shan-Jun, Wang Da-Yu, Zhang Wen-Zhu, Liang Wei-Jie
Department of Cardiovascular Medicine, Guangzhou Panyu Central Hospital, Panyu District Cardiovascular Disease Research Institute of Guangzhou, Guangzhou, P.R. China.
Medicine (Baltimore). 2017 Aug;96(32):e7634. doi: 10.1097/MD.0000000000007634.
The aim of the study was to evaluate the potential role of CD40/CD40 ligand (CD40L) and CD134/CD134 ligand (CD134L) in the development of coronary heart disease (CHD) via the performance of a case-control study.The research objects were 234 cases of CHD patients and 120 cases of well-matched normal controls. Following the separation of peripheral blood mononuclear cells (PBMCs), real-time quantitative PCR (qRT-PCR), Western blot, immunohistochemistry, and flow cytometry were applied for the detection of mRNA levels and expression levels of CD40/CD40L and CD134/CD134L; meanwhile, intercellular adhesion molecule-1 (ICAM-1) and Fas protein mRNA levels were detected using qRT-PCR.There was no statistical difference in the comparison of baseline characteristics between groups, indicating comparability between groups. qRT-PCR and Western blot analysis indicated that CD40/CD40L and CD134/CD134L mRNA and protein expression levels were all increased in the CHD group than those in the control group. Flow cytometry further confirmed the similar tendency. Meanwhile, ICAM-1 and Fas protein mRNA levels were elevated in the CHD group and positively correlated with the above parameters. Furthermore, CD40/CD40L expression rates were negatively correlated with gender and different types of CHD. Meanwhile, CD134/CD134L expressions were also higher in male patients, in patients with family history, previous history of hypertension, diabetes, and cerebrovascular diseases.CD40/CD40L and CD134/CD134L are increased and may have potential correlation with clinical pathological features of patients with CHD. Further in-depth exploration of costimulatory molecules for CHD guidance as well as intrinsic mechanisms are needed combined with in vivo and in vitro experiments.
本研究旨在通过病例对照研究评估CD40/CD40配体（CD40L）和CD134/CD134配体（CD134L）在冠心病（CHD）发生发展中的潜在作用。研究对象为234例冠心病患者和120例匹配良好的正常对照者。分离外周血单个核细胞（PBMCs）后，采用实时定量聚合酶链反应（qRT-PCR）、蛋白质免疫印迹法、免疫组织化学和流式细胞术检测CD40/CD40L和CD134/CD134L的mRNA水平和表达水平；同时，用qRT-PCR检测细胞间黏附分子-1（ICAM-1）和Fas蛋白mRNA水平。两组间基线特征比较无统计学差异，表明组间具有可比性。qRT-PCR和蛋白质免疫印迹分析表明，冠心病组CD40/CD40L和CD134/CD134L的mRNA和蛋白表达水平均高于对照组。流式细胞术进一步证实了类似趋势。同时，冠心病组ICAM-1和Fas蛋白mRNA水平升高，且与上述参数呈正相关。此外，CD40/CD40L表达率与性别及不同类型冠心病呈负相关。同时，男性患者、有家族史患者、既往有高血压、糖尿病和脑血管疾病史患者的CD134/CD134L表达也较高。CD40/CD40L和CD134/CD134L升高，可能与冠心病患者的临床病理特征存在潜在关联。需要结合体内和体外实验进一步深入探索共刺激分子对冠心病的指导作用及其内在机制。
